Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + pioglitazone
- Development stage
- Phase 4
- Lead developer
- Akums Drugs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dapagliflozin + Pioglitazone is a combination therapy used for the treatment of type 2 diabetes mellitus. **Dapagliflozin** is an SGLT2 inhibitor that blocks glucose reabsorption in the kidneys, promoting glucose excretion through urine. **Pioglitazone** enhances insulin sensitivity by activating PPARγ receptors, improving glucose utilization and reducing insulin resistance. This combination addresses both insulin resistance and excess glucose, providing comprehensive blood sugar control.
- Brand names
- Gluxit-ProSiena P
- Other names
- dapagliflozin/pioglitazone
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on dapagliflozin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + pioglitazone.